- Invest USD 250 million to advance R&D for neglected tropical diseases (NTDs) and malaria (over 5 years from 2021-2025)
- Implement a global access strategy for all new medicines launched
- Increase patients reached with strategic innovative medicines in LMICs1 by at least 200% by 2025 (vs. 2019)
- Increase by at least 50% the number of patients reached with global health flagship programs (malaria, leprosy, chagas, sickle cell disease) in LMICs1 by 2025 (vs. 2019)
Environmental sustainability
- 2025: Be carbon neutral in our own operations (Scope 1 and 2)2; Include environmental criteria in all supplier contracts
- 2030: Achieve carbon neutrality across our value chain (Scope 1, 2, 3)
- 2040: Achieve net zero carbon emissions across our value chain (Scope 1, 2, 3)3
Learn more about our efforts to reduce our impacts on climate
- 2025: Reduce water consumption in our operations by half4, with no water quality impacts from manufacturing effluents
- 2030: Be water neutral in all areas of our own operations versus 2016 baseline5, while actively enhancing water quality wherever we operate
- 2025: Eliminate polyvinyl chloride (PVC) in packaging6 and reduce the amount of waste sent for disposal by half4
- 2030: Be plastic neutral7, with all new products meeting sustainable design principles